Your browser doesn't support javascript.
loading
Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach.
Selig, Daniel J; Reed, Tyler; Chung, Kevin K; Kress, Adrian T; Stewart, Ian J; DeLuca, Jesse P.
Afiliación
  • Selig DJ; Department of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Reed T; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Chung KK; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Kress AT; Department of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Stewart IJ; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • DeLuca JP; Department of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Blood Purif ; 52(1): 25-31, 2023.
Article en En | MEDLINE | ID: mdl-35526522
ABSTRACT

INTRODUCTION:

The Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a hemoperfusion device that can remove pathogens from central circulation. However, the effect of Seraph 100 on achieving pharmacodynamic (PD) targets is not well described. We sought to determine the impact of Seraph 100 on ability to achieve PD targets for commonly used antibiotics.

METHODS:

Estimates of Seraph 100 antibiotic clearance were obtained via literature. For vancomycin and gentamicin, published pharmacokinetic models were used to explore the effect of Seraph 100 on ability to achieve probability of target attainment (PTA). For meropenem and imipenem, the reported effect of continuous kidney replacement therapy (CKRT) on achieving PTA was used to extrapolate decisions for Seraph 100.

RESULTS:

Seraph 100 antibiotic clearance is likely less than 0.5 L/h for most antibiotics. Theoretical Seraph 100 clearance up to 0.5 L/h and 2 L/h had a negligible effect on vancomycin PTA in virtual patients with creatinine clearance (CrCl) = 14 mL/min and CrCl >14 mL/min, respectively. Theoretical Seraph 100 clearance up to 0.5 L/h and 2 L/h had a negligible effect on gentamicin PTA in virtual patients with CrCl = 120 mL/min and CrCl <60 mL/min, respectively. CKRT intensity resulting in antibiotic clearance up to 2 L/h generally does not require dose increases for meropenem or imipenem. As Seraph 100 is prescribed intermittently and likely contributes far less to antibiotic clearance, dose increases would also not be required.

CONCLUSION:

Seraph 100 clearance of vancomycin, gentamicin, meropenem, and imipenem is likely clinically insignificant. There is insufficient evidence to recommend increased doses. For aminoglycosides, we recommend extended interval dosing and initiating Seraph 100 at least 30 min to 1 h after completion of infusion to avoid the possibility of interference with maximum concentrations.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hemoperfusión / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Purif Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hemoperfusión / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Purif Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos